Brief: Aditxt’S Target Acquisition Appili Therapeutics Announces Alignment With FDA On Development Requirements For ATI-1801 Topical Antiparasitic Product NDA Submission
31/10/2024 12:32
Oct 31 (Reuters) - Aditxt Inc ADTX.O :
* ADITXT’S TARGET ACQUISITION APPILI THERAPEUTICS ANNOUNCES
ALIGNMENT WITH FDA ON DEVELOPMENT REQUIREMENTS FOR ATI-1801
TOPICAL ANTIPARASITIC PRODUCT NDA SUBMISSION
Source text: ID:nBw2SNklPa
Further company coverage: ADTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Appili Therapeutics
See all newsBrief: Appili Therapeutics Announces Closing Of Second Tranche Of Non-Brokered Private Placement
Brief: Appili Therapeutics Closes First Tranche Of Non-Brokered Private Placement
Brief: Appili Therapeutics Announces Proposed Non-Brokered Private Placement
Brief: Appili Therapeutics Announces Formal Termination Of Arrangement Agreement With Aditxt
Brief: Appili Therapeutics Announces New Patents Granted For Commercial Stage Asset Likmez